Who Buys Nilotinib from India — 56 Importers Behind a $1.2M Market

The importers of Nilotinib from India can be categorized into several segments:

1. Distributors: Entities like SOFTCARE INTERNATIONAL (PVT) LTD in Sri Lanka, which accounted for $1.10 million in imports, function as intermediaries, purchasing large quantities to supply to healthcare providers. Their buying behavior typically involves bulk orders to benefit from economies of scale, with a focus on maintaining a steady supply chain to meet market demand.

2. Hospital Groups: While specific hospital groups are not identified in the top buyers, such entities usually procure Nilotinib directly for patient treatment. Their purchasing patterns are characterized by regular, smaller orders aligned with patient needs and treatment schedules.

3. Retail Chains: Retail pharmacies may import Nilotinib to cater to outpatient prescriptions. Their orders are generally smaller and more frequent, aiming to manage inventory effectively and respond to prescription trends.

4. Government Procurement: Government agencies or international organizations like UNICEF and the Global Fund may engage in tender-based purchasing to supply public healthcare facilities. These procurements are often large-scale and periodic, driven by public health initiatives and budget allocations.

5. Re-exporters: Companies such as ASMITA COMERCIO SU LDA in Angola, importing $0.01 million worth of Nilotinib, may act as re-exporters, purchasing the drug for distribution to neighboring regions. Their buying behavior includes bulk purchases intended for redistribution, influenced by regional demand and trade agreements.

6. Contract Manufacturers: Entities like DR. REDDY'S BEIJING PHARMACEUTICAL CO. LTD in China, listed among the top buyers, may import Nilotinib for further processing or formulation. Their procurement patterns depend on production schedules and contractual obligations, often involving substantial quantities to support manufacturing operations.

For the top five importing countries of Nilotinib from India, the import regulations are as follows:

The demand for Nilotinib in importing countries is primarily driven by the prevalence of chronic myeloid leukemia (CML), a type of blood cancer that Nilotinib effectively treats. According to the World Health Organization (WHO), leukemia accounts for approximately 474,500 new cases globally each year, with CML representing about 15-20% of adult cases. This significant disease burden necessitates access to effective treatments like Nilotinib.

Government healthcare programs and the expansion of universal health coverage also play crucial roles in driving demand. Many countries have included Nilotinib in their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which recommends Nilotinib for the treatment of CML. Additionally, international procurement mechanisms, such as those facilitated by the Medicines Patent Pool (MPP), have expanded access to generic versions of Nilotinib in low- and middle-income countries, further increasing availability and affordability. Tender-based purchasing by government agencies and international organizations ensures a steady supply of the drug, contributing to market stability and growth.

The importers of Nilotinib from India can be categorized into several segments:

1. Distributors: Entities like SOFTCARE INTERNATIONAL (PVT) LTD in Sri Lanka, which accounted for $1.10 million in imports, function as intermediaries, purchasing large quantities to supply to healthcare providers. Their buying behavior typically involves bulk orders to benefit from economies of scale, with a focus on maintaining a steady supply chain to meet market demand.

2. Hospital Groups: While specific hospital groups are not identified in the top buyers, such entities usually procure Nilotinib directly for patient treatment. Their purchasing patterns are characterized by regular, smaller orders aligned with patient needs and treatment schedules.

3. Retail Chains: Retail pharmacies may import Nilotinib to cater to outpatient prescriptions. Their orders are generally smaller and more frequent, aiming to manage inventory effectively and respond to prescription trends.

4. Government Procurement: Government agencies or international organizations like UNICEF and the Global Fund may engage in tender-based purchasing to supply public healthcare facilities. These procurements are often large-scale and periodic, driven by public health initiatives and budget allocations.

5. Re-exporters: Companies such as ASMITA COMERCIO SU LDA in Angola, importing $0.01 million worth of Nilotinib, may act as re-exporters, purchasing the drug for distribution to neighboring regions. Their buying behavior includes bulk purchases intended for redistribution, influenced by regional demand and trade agreements.

6. Contract Manufacturers: Entities like DR. REDDY'S BEIJING PHARMACEUTICAL CO. LTD in China, listed among the top buyers, may import Nilotinib for further processing or formulation. Their procurement patterns depend on production schedules and contractual obligations, often involving substantial quantities to support manufacturing operations.

For the top five importing countries of Nilotinib from India, the import regulations are as follows:

The demand for Nilotinib in importing countries is primarily driven by the prevalence of chronic myeloid leukemia (CML), a type of blood cancer that Nilotinib effectively treats. According to the World Health Organization (WHO), leukemia accounts for approximately 474,500 new cases globally each year, with CML representing about 15-20% of adult cases. This significant disease burden necessitates access to effective treatments like Nilotinib.

Government healthcare programs and the expansion of universal health coverage also play crucial roles in driving demand. Many countries have included Nilotinib in their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which recommends Nilotinib for the treatment of CML. Additionally, international procurement mechanisms, such as those facilitated by the Medicines Patent Pool (MPP), have expanded access to generic versions of Nilotinib in low- and middle-income countries, further increasing availability and affordability. Tender-based purchasing by government agencies and international organizations ensures a steady supply of the drug, contributing to market stability and growth.